Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Wang X, Khalil RA.

Adv Pharmacol. 2018;81:241-330. doi: 10.1016/bs.apha.2017.08.002. Epub 2017 Sep 19.

PMID:
29310800
2.

Editorial: GPCRs and Cancer.

Chen S.

Front Genet. 2017 Oct 31;8:162. doi: 10.3389/fgene.2017.00162. eCollection 2017. No abstract available.

3.

Direct thrombin inhibition with dabigatran attenuates pressure overload-induced cardiac fibrosis and dysfunction in mice.

Dong A, Mueller P, Yang F, Yang L, Morris A, Smyth SS.

Thromb Res. 2017 Nov;159:58-64. doi: 10.1016/j.thromres.2017.09.016. Epub 2017 Sep 21.

PMID:
28982031
4.

Effects of silenced PAR-2 on cell proliferation, invasion and metastasis of esophageal cancer.

Chen J, Xie L, Zheng Y, Liu C.

Oncol Lett. 2017 Oct;14(4):4115-4121. doi: 10.3892/ol.2017.6711. Epub 2017 Aug 3.

5.

Tissue-type plasminogen activator regulates macrophage activation and innate immunity.

Mantuano E, Azmoon P, Brifault C, Banki MA, Gilder AS, Campana WM, Gonias SL.

Blood. 2017 Sep 14;130(11):1364-1374. doi: 10.1182/blood-2017-04-780205. Epub 2017 Jul 6.

PMID:
28684538
6.

Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Liu J, Khalil RA.

Prog Mol Biol Transl Sci. 2017;148:355-420. doi: 10.1016/bs.pmbts.2017.04.003. Epub 2017 May 10.

PMID:
28662828
7.

The Role of Proteinase-Activated Receptors 1 and 2 in the Regulation of Periodontal Tissue Metabolism and Disease.

Rovai ES, Holzhausen M.

J Immunol Res. 2017;2017:5193572. doi: 10.1155/2017/5193572. Epub 2017 Apr 19. Review.

8.

Regulation of intestinal permeability: The role of proteases.

Van Spaendonk H, Ceuleers H, Witters L, Patteet E, Joossens J, Augustyns K, Lambeir AM, De Meester I, De Man JG, De Winter BY.

World J Gastroenterol. 2017 Mar 28;23(12):2106-2123. doi: 10.3748/wjg.v23.i12.2106. Review.

9.

Protease Activated Receptor 2 (PAR2) Induces Long-Term Depression in the Hippocampus through Transient Receptor Potential Vanilloid 4 (TRPV4).

Shavit-Stein E, Artan-Furman A, Feingold E, Ben Shimon M, Itzekson-Hayosh Z, Chapman J, Vlachos A, Maggio N.

Front Mol Neurosci. 2017 Mar 2;10:42. doi: 10.3389/fnmol.2017.00042. eCollection 2017.

10.

Antidermatophytic and Protease-inhibiting Activities of Zerumbone: A Natural Sesquiterpene from the Rhizome of Zingiber zerumbet (L.) Roscoe ex J.E; Smith.

Jyothilakshmi M, Jyothis M, Narayanan GN, Latha MS.

Pharmacogn Mag. 2017 Jan-Mar;13(49):2-6. doi: 10.4103/0973-1296.197649.

11.

Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice.

Shi K, Damhofer H, Daalhuisen J, Ten Brink M, Richel DJ, Spek CA.

Mol Med. 2017 Feb 6;23. doi: 10.2119/molmed.2016.00214. [Epub ahead of print]

12.

Site-specific O-Glycosylation by Polypeptide N-Acetylgalactosaminyltransferase 2 (GalNAc-transferase T2) Co-regulates β1-Adrenergic Receptor N-terminal Cleavage.

Goth CK, Tuhkanen HE, Khan H, Lackman JJ, Wang S, Narimatsu Y, Hansen LH, Overall CM, Clausen H, Schjoldager KT, Petäjä-Repo UE.

J Biol Chem. 2017 Mar 17;292(11):4714-4726. doi: 10.1074/jbc.M116.730614. Epub 2017 Feb 6.

PMID:
28167537
13.

Protease-Activated Receptor 2 Promotes Pro-Atherogenic Effects through Transactivation of the VEGF Receptor 2 in Human Vascular Smooth Muscle Cells.

Indrakusuma I, Romacho T, Eckel J.

Front Pharmacol. 2017 Jan 4;7:497. doi: 10.3389/fphar.2016.00497. eCollection 2016.

14.

Protease-activated receptors in kidney disease progression.

Palygin O, Ilatovskaya DV, Staruschenko A.

Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1140-F1144. doi: 10.1152/ajprenal.00460.2016. Epub 2016 Oct 12. Review.

15.

Proteinase activated receptor-2 counterbalances the vascular effects of endothelin-1 in fibrotic tight-skin mice.

Roviezzo F, Brancaleone V, Mattera Iacono V, Bertolino A, De Cunto G, Vellecco V, Lungarella G, Lucattelli M, Cirino G.

Br J Pharmacol. 2017 Nov;174(22):4032-4042. doi: 10.1111/bph.13618. Epub 2016 Oct 5.

PMID:
27625162
16.

Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice.

Waasdorp M, Duitman J, Florquin S, Spek CA.

Sci Rep. 2016 Sep 13;6:33030. doi: 10.1038/srep33030.

17.

Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection.

Rosero RA, Villares GJ, Bar-Eli M.

Front Genet. 2016 Jun 15;7:112. doi: 10.3389/fgene.2016.00112. eCollection 2016. Review.

18.

Inhibition of Protease-Activated Receptor 1 Does not Affect Dendritic Homeostasis of Cultured Mouse Dentate Granule Cells.

Schuldt G, Galanis C, Strehl A, Hick M, Schiener S, Lenz M, Deller T, Maggio N, Vlachos A.

Front Neuroanat. 2016 Jun 13;10:64. doi: 10.3389/fnana.2016.00064. eCollection 2016.

19.

Thrombin Receptor-Activating Protein (TRAP)-Activated Akt Is Involved in the Release of Phosphorylated-HSP27 (HSPB1) from Platelets in DM Patients.

Tokuda H, Kuroyanagi G, Tsujimoto M, Matsushima-Nishiwaki R, Akamatsu S, Enomoto Y, Iida H, Otsuka T, Ogura S, Iwama T, Kojima K, Kozawa O.

Int J Mol Sci. 2016 May 14;17(5). pii: E737. doi: 10.3390/ijms17050737.

20.

Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood.

Blatt AZ, Saggu G, Kulkarni KV, Cortes C, Thurman JM, Ricklin D, Lambris JD, Valenzuela JG, Ferreira VP.

J Immunol. 2016 Jun 1;196(11):4671-4680. doi: 10.4049/jimmunol.1600040. Epub 2016 Apr 25.

Supplemental Content

Support Center